DaVita HealthCare Partners Inc (DVA) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of DaVita HealthCare Partners Inc stock $219, price $188, upside +16.7%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range $65.42 – $240.96 · fair‑value band $133.75 – $312.95 · the $187.50 price screens below the $218.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow DaVita HealthCare Partners in your weekly email
Every Wednesday you see whether DaVita HealthCare Partners is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
Show moreShow less
It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business.
The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Stock analysis
DaVita HealthCare Partners Inc (DVA) currently trades at $187.50, while our model-based Fair Value estimate is $218.90, implying the stock looks roughly 14.3% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $235.36 per share, and 16 of the 22 models we run sit above the $187.50 price.
Bear case: the Economic Profit group reads lowest at $80.75, and 6 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $133.75 (bear) to $312.95 (bull), the price of $187.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
DaVita HealthCare Partners Inc reported revenue of $13.6B in FY2025 versus $11.6B in FY2021, a compound +4.1%/yr. Reported net income was $747M in FY2025, compounding −6.5%/yr from FY2021.
Key figures
Market cap $12.4B Large · P/E ratio 14.2 · P/S ratio 1.26 · EPS (TTM) $13.21 · Net margin 6.5% · Return on equity 96.8% · Return on assets (EBIT) 10.3% · Operating margin 15.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 81% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −23% fair-value upside, at 17%, DVA screens cheaper than that median.
Fair Value models
Bear$133.75Fair Value $218.90Bull$312.95
Price $187.50 · Upside +16.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($11.07 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Start year 2020 (pandemic). Over 10 years: −0.1% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+7.5%
Earnings growth per share plus dividend.
From 2014 to 2025, about 78% of the growth in earnings per share came from share buybacks, and equity is negative: the buybacks are partly paid with debt. That cannot be repeated indefinitely.
Earnings per share, growth per year+7.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.1% vs 9.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +1.4% a year for the price and +0.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: DaVita's large US dialysis network and Integrated Kidney Care expansion provide scale, yet high leverage and payer mix pressures limit margin durability.
Main risk: HHS initiatives to promote competition, expand home dialysis and scrutinize anticompetitive practices of dominant firms could alter reimbursement structures or market access for DaVita's in-center network.
Bull case: DaVita could leverage its scale and existing Integrated Kidney Care platform to lead in value-based arrangements and home modalities, capturing earlier-stage patients and offsetting any regulatory or competitive pressures.
Bear case: If reimbursement reforms and rival value-based or home models gain traction, DaVita's core in-center dialysis volumes and margins could decline materially over several years.
DaVita operates one of the largest U.S. dialysis networks and has expanded its Integrated Kidney Care platform, which generated forty million dollars more adjusted operating income than expected in the second quarter. Commercial payer mix pressures and competition still constrain margins even as value-based arrangements grow. Our models currently see it as undervalued. Will the shift toward risk-based contracts improve overall economics, or will reimbursement challenges cap the upside?
Compare DaVita HealthCare Partners Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 236 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+16.7% · Above median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets6.2% · Above median
Net margin (12 months)9.4% · Above median
Operating margin (12 months)15.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.6% · Below median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)14.2× · Cheaper than median
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DaVita HealthCare Partners Inc (DVA) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of $218.90 versus a price of $187.50, about +17% upside (undervalued).
What is the fair value of DVA?
Our model-based fair value for DaVita HealthCare Partners Inc is $218.90 (as of Nov 2, 2026), built from audited fundamentals. The current price: $187.50.
What is the quality score of DVA?
DaVita HealthCare Partners Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DaVita HealthCare Partners Inc (DVA)?
Our model-based price target is the fair value of $218.90 (as of Nov 2, 2026) from 22 valuation models. Cautious scenario $133.75, optimistic scenario $312.95. It is a calculation from audited fundamentals, not an analyst target.
What is the DaVita HealthCare Partners Inc stock forecast for 2026?
Our models put fair value at $218.90, about +17% upside versus a price of $187.50 (undervalued). Cautious scenario $133.75, optimistic scenario $312.95. The calculation is refreshed regularly with new filings.
What is the revenue of DaVita HealthCare Partners Inc (DVA)?
DaVita HealthCare Partners Inc reported trailing-twelve-month revenue of about $14.2B (latest available figure, as of Nov 2, 2026).
What growth is priced into DaVita HealthCare Partners Inc (DVA)?
For today's price to be fair in a discounted-cash-flow model, DaVita HealthCare Partners Inc would have to grow free cash flow by +3.8 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of DVA use?
Our models discount DaVita HealthCare Partners Inc at 8.8 %: a base by market capitalisation (large), damped by beta 0.80, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DaVita HealthCare Partners Inc that is +3.8 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has DaVita HealthCare Partners Inc (DVA) delivered so far?
Over the past 5 years revenue at DaVita HealthCare Partners Inc grew +3.4 % a year. The price currently implies +3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DaVita HealthCare Partners Inc (DVA) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into DaVita HealthCare Partners Inc (+3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DaVita HealthCare Partners Inc (DVA)?
The free-cash-flow yield on the price is 10.58 %: that much free cash flow DaVita HealthCare Partners Inc produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DaVita HealthCare Partners Inc (DVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DaVita HealthCare Partners Inc it is $218.90 per share (as of Nov 2, 2026), against a price of $187.50. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is DaVita HealthCare Partners Inc stock overvalued or undervalued in 2026?
As of Nov 2, 2026, DVA trades below its calculated fair value: price $187.50, fair value $218.90, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DVA?
No. The price is what the market pays today ($187.50); the fair value is what the company's own numbers justify ($218.90). For DaVita HealthCare Partners Inc the two are $31.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is DaVita HealthCare Partners Inc worth?
The market values DaVita HealthCare Partners Inc at about $12.4B (market capitalisation, as of Nov 2, 2026). Per share that is $187.50; our models calculate a fair value of $218.90 per share.
What do the bullish and bearish scenarios say about DVA?
Our models span a range for DaVita HealthCare Partners Inc: cautious scenario $133.75, base $218.90, optimistic $312.95 per share (as of Nov 2, 2026, price $187.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DVA?
DaVita HealthCare Partners Inc trades at a price-to-earnings ratio of 14.2 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $218.90 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 15.7 (reported for FY2025: 22.1). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), earnings ex one-offs: 10.7. Other multiples: PEG 0.5, P/S 1.3, EV/EBITDA 11.1.
What is the PEG ratio of DVA?
The PEG ratio of DaVita HealthCare Partners Inc is 0.46 (P/E divided by earnings growth, as of Nov 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of DaVita HealthCare Partners Inc (DVA)?
Balance-sheet figures for DaVita HealthCare Partners Inc (as of Nov 2, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is DVA from its 52-week high?
DaVita HealthCare Partners Inc trades at $187.50, about 22% below its 52-week high of $240.96 and 81% above the low of $103.87 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $218.90 is for.
Which stocks are comparable to DaVita HealthCare Partners Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DaVita HealthCare Partners Inc stock attractive at the current price?
The data as of Nov 2, 2026: price $187.50, calculated fair value $218.90 (+17%), Quality Score 60/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DVA calculated?
We run DaVita HealthCare Partners Inc through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $218.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2 % above its aggregate fair value. DaVita HealthCare Partners Inc currently trades 14 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DaVita HealthCare Partners Inc (DVA)?
The closing price on Oct 30, 2026 was $187.50. Our model-based fair value is $218.90, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DaVita HealthCare Partners Inc right now?
A fairly wide model range ($133.75 to $312.95) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of DaVita HealthCare Partners Inc (DVA) come from?
Earnings per share at DaVita HealthCare Partners Inc grew +13.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.3 %, EBIT margin +2.3 %, tax rate +2.3 %, residual (interest, one-offs) −1.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of DaVita HealthCare Partners Inc
How large is the market capitalisation of DaVita HealthCare Partners Inc (DVA)?
The market capitalisation of DaVita HealthCare Partners Inc is $12.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DaVita HealthCare Partners Inc (DVA)?
The price-to-sales ratio of DaVita HealthCare Partners Inc is 1.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DaVita HealthCare Partners Inc (DVA)?
Earnings per share at DaVita HealthCare Partners Inc are $13.21 (price ÷ EPS = P/E 14.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DaVita HealthCare Partners Inc (DVA)?
The net margin of DaVita HealthCare Partners Inc is 6.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DaVita HealthCare Partners Inc (DVA)?
The return on equity (ROE) of DaVita HealthCare Partners Inc is 96.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DaVita HealthCare Partners Inc (DVA)?
On an EBIT basis the return on assets of DaVita HealthCare Partners Inc is 10.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DaVita HealthCare Partners Inc (DVA)?
The operating margin of DaVita HealthCare Partners Inc is 15.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DaVita HealthCare Partners Inc (DVA)?
Revenue at DaVita HealthCare Partners Inc is growing +4.6% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DaVita HealthCare Partners Inc (DVA)?
Earnings per share at DaVita HealthCare Partners Inc are growing +66.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DaVita HealthCare Partners Inc (DVA) carry?
The net debt of DaVita HealthCare Partners Inc is $14.3B (fiscal year 2025, ≈ 10.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DaVita HealthCare Partners Inc in the live analysis
One click puts DaVita HealthCare Partners Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 2, 2026